X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.fiercebiotech.com/biotech/vertex-scores-phase-3-gold-after-next-gen-cystic-fibrosis-treatment-goes-against-trikafta
https://www.fiercepharma.com/pharma/while-vertex-gears-next-generation-cf-treatment-trikafta-remains-formidable
https://www.fiercepharma.com/pharma/nices-trikafta-snub-could-portend-another-pricing-standoff-between-vertex-and-uk
https://www.businesswire.com/news/home/20230426005815/en/Vertex-Announces-U.S.-FDA-Approval-for-TRIKAFTA%C2%AE-elexacaftortezacaftorivacaftor-and-ivacaftor-in-Children-With-Cystic-Fibrosis-Ages-2-Through-5-With-Certain-Mutations
https://www.businesswire.com/news/home/20230426005815/en/Vertex-Announces-U.S.-FDA-Approval-for-TRIKAFTA%C2%AE-elexacaftortezacaftorivacaftor-and-ivacaftor-in-Children-With-Cystic-Fibrosis-Ages-2-Through-5-With-Certain-Mutations
https://www.pharmatimes.com/news/european_commission_approves_cystic_fibrosis_treatment_for_six_to_11-year-olds_1386105
https://www.biospace.com/article/releases/vertex-announces-letter-of-intent-with-pan-canadian-pharmaceutical-alliance-for-public-reimbursement-of-cftr-modulators-extended-to-include-trikafta-and-174-elexacaftor-tezacaftor-ivacaftor-and-ivacaftor-/?s=100
https://www.fiercepharma.com/pharma/vertex-s-cf-drug-trikafta-drives-29-sales-growth-q4-but-analysts-bemoan-weak-near-term
https://www.biospace.com/article/releases/vertex-announces-fda-approvals-of-trikafta-elexacaftor-tezacaftor-ivacaftor-and-ivacaftor-symdeko-tezacaftor-ivacaftor-and-ivacaftor-and-kalydeco-ivacaftor-for-use-in-people-with-cf-with-certain-rare-mutations/?s=74
https://www.businesswire.com/news/home/20200924005175/en/Vertex-to-Present-New-Data-at-European-and-North-American-Virtual-Cystic-Fibrosis-Conferences-Highlighting-Long-Term-Use-of-CFTR-Modulators
https://icer-review.org/announcements/icer-issues-final-report-and-policy-recommendations-on-treatments-for-cystic-fibrosis/
https://www.ema.europa.eu/en/documents/overview/kaftrio-epar-medicine-overview_en.pdf
https://www.europeanpharmaceuticalreview.com/news/126549/vertexs-kaftrio-approved-for-use-in-europe-and-made-accessible-on-the-nhs/
http://www.pharmatimes.com/news/vertex_and_nhs_wales_agree_on_kaftrio_reimbursement_1345325
https://via.tt.se/pressmeddelande/vertex-announces-expansion-of-reimbursement-agreement-with-nhs-england-to-include-kaftrio-ivacaftortezacaftorelexacaftor-in-combination-with-kalydeco-ivacaftor?publisherId=259167&releaseId=3279501#:~:text=Vertex%20Pharmaceuticals%20Incorporated%20(Nasdaq%3A%20VRTX,mg%2C%20ahead%20of%20the%20medicine's
https://www.raps.org/news-and-articles/news-articles/2020/6/ema-recommends-eight-new-medicines-refuses-one
https://www.fiercepharma.com/pharma/even-amid-a-pandemic-vertex-raises-guidance-thanks-to-gangbusters-start-for-trikafta
https://endpts.com/vertexs-cystic-fibrosis-drugs-work-but-theyre-too-expensive-icer-finds/
https://www.fiercepharma.com/pharma/as-trikafta-launch-got-underway-vertex-s-leiden-scored-18-79m-final-full-year-as-ceo
https://www.biopharmadive.com/news/vertex-trikafta-launch-cystic-fibrosis-leiden/571452/
https://www.raps.org/news-and-articles/news-articles/2019/11/fda-approves-5-new-costly-drugs-well-ahead-of-acti
http://www.pharmatimes.com/news/impressive_results_for_trikafta_in_cystic_fibrosis_1315050
https://www.fiercepharma.com/pharma/vertex-s-triple-combo-launch-trikafta-underway-as-drugmaker-humming-analyst-says
http://www.pharmatimes.com/news/trikafta_wins_fda_approval_for_cf_1314112
https://www.fiercepharma.com/pharma/vertex-lands-blockbuster-triple-combo-nod-for-cf-drug-trikafta-5-months-early
https://www.fda.gov/news-events/press-announcements/fda-approves-new-breakthrough-therapy-cystic-fibrosis
https://www.forbes.com/sites/danadovey/2019/10/22/fda-approves-cystic-fibrosis-drug-applicable-for-90-percent-of-patients/#23a9b1be5cd2
https://www.raps.org/regulatory-focus/news-articles/2017/12/regulatory-explainer-everything-you-need-to-know-about-fdas-priority-review-vouchers
https://cysticfibrosisnewstoday.com/2019/08/26/fda-grants-priority-review-vertex-1st-triple-combo-cf/
https://www.businesswire.com/news/home/20190820005233/en/FDA-Accepts-New-Drug-Application-VX-445-Elexacaftor
Market Place
Share 
